DFTX Definium Therapeutics, Inc.
Definium Therapeutics, Inc. (DFTX) is expected to report earnings on February 8, 2027, after the market close. The consensus earnings estimate is a loss of $0.51 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -12.5% since its last earnings release on November 9, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc. is developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Definium Therapeutics Inc., formerly known as Mind Medicine Inc., is based in NEW YORK.
Sector
Healthcare
Industry
Biotechnology
Held By 2 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.